Ownership and insider activity for Lantern Pharma Inc. (LTRN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer.
Price
| Price | $1.93 |
| Market Cap | $25M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-12 | Schalop Lee Troy | P-Purchase | 48,544 | $100K |
| 2026-05-12 | Schalop Lee Troy | P-Purchase | 48,544 | $110K |
| 2026-05-12 | KEYSER D JEFFREY | P-Purchase | 48,544 | $100K |
| 2026-05-12 | KEYSER D JEFFREY | P-Purchase | 48,544 | $110K |
| 2026-01-09 | KEYSER D JEFFREY | A-Award | 28,844 | $101K |
| 2026-01-09 | KEYSER D JEFFREY | A-Award | 25,000 | $87K |
| 2026-01-09 | Maccecchini Maria-Luisa | A-Award | 25,000 | $87K |
| 2026-01-09 | Maccecchini Maria-Luisa | A-Award | 21,152 | $74K |
| 2026-01-09 | Chandru Vijay | A-Award | 25,000 | $87K |
| 2026-01-09 | Chandru Vijay | A-Award | 17,307 | $60K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $445163 | $1.2M | $19.2M | $51.5M | $37.2M | $21.9M | $7.5M | $4.4M |
| Short-term Investments | 0 | 0 | 0 | $19.2M | $18.0M | $19.4M | $16.5M | $5.7M |
| Receivables | 0 | 0 | 0 | $181000 | 0 | $860000 | 0 | $30000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $445163 | $1.2M | $20.2M | $72.7M | $58.7M | $43.3M | $25.2M | $10.8M |
| Property, Plant & Equipment | $4668 | $8758 | $21507 | $216188 | $95695 | $280422 | $287425 | $107.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $449831 | $1.4M | $20.4M | $74.0M | $58.8M | $43.6M | $25.6M | $11.0M |
| Accounts Payable | $97629 | $478292 | $432339 | $2.2M | 0 | $942211 | 0 | $4.4M |
| Short-term Debt | 0 | 0 | 0 | $152058 | 0 | 0 | 0 | $78.5M |
| Total Current Liabilities | $651629 | $489292 | $552339 | $2.3M | $2.8M | $2.7M | $4.3M | $4.5M |
| Long-term Debt | 0 | 0 | $108500 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $651629 | $489292 | $660839 | $2.4M | $2.8M | $2.7M | $4.4M | $4.5M |
| Retained Earnings | -$4.3M | -$6.8M | -$12.7M | -$25.0M | -$39.3M | -$55.2M | -$76.0M | -$93.1M |
| Total Equity | -$201798 | $943284 | $19.7M | $71.6M | $56.0M | $40.9M | $21.2M | $6.5M |
| Total Debt | 0 | 0 | $108500 | $204948 | $52890 | $234471 | $243657 | $78.5M |
| Net Debt | -$445163 | -$1.2M | -$19.1M | -$70.5M | -$55.1M | -$41.1M | -$23.8M | $68.4M |
| Working Capital | -$206466 | $743526 | $19.7M | $70.4M | $55.9M | $40.7M | $20.9M | $6.3M |
Financial Health
| Debt / Equity | -0.01 |
| Current Ratio | 1.96 |
Profitability
| Return on Equity | -456.35% |
| Return on Invested Capital | -358.04% |
| Return on Assets | -216.84% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · ATNM · BCAB · CALC · ELUT · LVTX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of LTRN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks